SCHEMBL2437151

SCHEMBL2437151

CCOC(=O)C1(COc2ccc(-c3ccc(C#N)cc3)cc2)CCN(C(=O)c2ccc(Cl)cc2)C1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 1/20 0.68
PTGER2 P43116 1/20 0.68
PTGDR Q13258 1/20 0.68
HRH2 P25021 2/20 0.48
HRH1 P35367 2/20 0.48
HRH3 Q9Y5N1 1/20 0.48
CYP3A4 P08684 3/20 0.47
CYP2D6 P10635 1/20 0.47
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
USP2 O75604 3/20 0.46
TSHR P16473 3/20 0.46
CYP2C9 P11712 2/20 0.46
CYP1A2 P05177 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
P4HB P07237 1/20 0.45
GAA P10253 1/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 1/20 0.44
TACR3 P29371 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2435176 0.93 PTGER4 (0.80) PTGER4PTGER2PTGDRHRH2HRH1
SCHEMBL2433396 0.92 PTGER2 (0.67) PTGER4PTGER2PTGDRHRH2HRH1
SCHEMBL2440236 0.89 PTGER2 (0.53) PTGER4PTGER2PTGDRHRH2HRH1
SCHEMBL3322222 0.86 PTGER4 (0.50) PTGER4PTGER2PTGDRHRH2HRH1
SCHEMBL2433795 0.85 PTGER2 (0.56) PTGER4PTGER2PTGDRHRH2HRH1
SCHEMBL2436344 0.85 PTGER4 (0.49) PTGER4PTGER2PTGDRHRH2HRH1
SCHEMBL2442842 0.84 PTGER4 (0.47) PTGER4PTGER2PTGDRHRH2HRH1
SCHEMBL2438797 0.82 PTGER4 (0.59) PTGER4PTGER2PTGDRHRH2HRH1
SCHEMBL3627498 0.81 PTGER2 (0.70) PTGER4PTGER2PTGDRHRH2HRH1
SCHEMBL2434921 0.81 PTGER2 (0.62) PTGER4PTGER2PTGDRHRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278343-B2 Pyrrolidines PFIZER INC. (US) 2012-10-02 US disclosed
US-8278343-B2 Pyrrolidines PFIZER INC. (US) 2012-10-02 US disclosed
US-8278343-B2 Pyrrolidines PFIZER INC. (US) 2012-10-02 US disclosed
EP-2364296-A1 PYRROLIDINES Pfizer Limited (GB) 2011-09-14 EP disclosed
WO-2010052625-A1 PYRROLIDINES PFIZER LIMITED (GB) 2010-05-14 WO disclosed
WO-2010052625-A1 PYRROLIDINES PFIZER LIMITED (GB) 2010-05-14 WO disclosed
US-20100120793-A1 Pyrrolidines PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) 2010-05-13 US disclosed
US-20100120793-A1 Pyrrolidines PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) 2010-05-13 US disclosed
US-20100120793-A1 Pyrrolidines PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120793-A1 Pyrrolidines PTGER2, PTGDR2, PTGES2 PTGER4 11/4885PTGER2 1/4885PTGDR 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.